These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 18607151)

  • 21. Challenges associated with metabolic syndrome.
    Spinler SA
    Pharmacotherapy; 2006 Dec; 26(12 Pt 2):209S-217S. PubMed ID: 17125447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C-reactive protein and the metabolic syndrome: useful addition to the cardiovascular risk profile?
    Szmitko PE; Verma S
    J Cardiometab Syndr; 2006; 1(1):66-9; quiz 70-1. PubMed ID: 17675894
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The metabolic syndrome as a prohypertensive state.
    Mulé G; Cerasola G
    Am J Hypertens; 2008 Jan; 21(1):8. PubMed ID: 18268791
    [No Abstract]   [Full Text] [Related]  

  • 24. Metabolic syndrome in men with low testosterone levels: relationship with cardiovascular risk factors and comorbidities and with erectile dysfunction.
    García-Cruz E; Leibar-Tamayo A; Romero J; Piqueras M; Luque P; Cardeñosa O; Alcaraz A
    J Sex Med; 2013 Oct; 10(10):2529-38. PubMed ID: 23898860
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Operative risk factors in the metabolic syndrome: is it lipids and high blood pressure or are there direct vascular effects of insulin resistance and obesity?
    Ukkola O
    Curr Cardiol Rep; 2006 Nov; 8(6):427-32. PubMed ID: 17059794
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adipocytes and cardiometabolic risk.
    Allende-Vigo MZ
    Am J Ther; 2012 Jul; 19(4):294-9. PubMed ID: 21150766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic syndrome: cardiovascular risk assessment and management.
    Wong ND
    Am J Cardiovasc Drugs; 2007; 7(4):259-72. PubMed ID: 17696567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between insulin resistance and the development of cardiovascular disease.
    Ormazabal V; Nair S; Elfeky O; Aguayo C; Salomon C; Zuñiga FA
    Cardiovasc Diabetol; 2018 Aug; 17(1):122. PubMed ID: 30170598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Omentin: linking metabolic syndrome and cardiovascular disease.
    Zhou JY; Chan L; Zhou SW
    Curr Vasc Pharmacol; 2014 Jan; 12(1):136-43. PubMed ID: 22724476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolic syndrome and Alzheimer's disease: a link to a vascular hypothesis?
    Milionis HJ; Florentin M; Giannopoulos S
    CNS Spectr; 2008 Jul; 13(7):606-13. PubMed ID: 18622365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High cardiometabolic risk in healthy Chilean adolescents: associations with anthropometric, biological and lifestyle factors.
    Burrows R; Correa-Burrows P; Reyes M; Blanco E; Albala C; Gahagan S
    Public Health Nutr; 2016 Feb; 19(3):486-93. PubMed ID: 25990645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epidemiology of the insulin resistance syndrome.
    Meigs JB
    Curr Diab Rep; 2003 Feb; 3(1):73-9. PubMed ID: 12643149
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The metabolic syndrome. Part II: its mechanisms of development and its complications].
    Pacholczyk M; Ferenc T; Kowalski J
    Postepy Hig Med Dosw (Online); 2008 Oct; 62():543-58. PubMed ID: 18936730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolic syndrome, subclinical coronary atherosclerosis, and cardiovascular risk.
    Campbell CY; Nasir K; Blumenthal RS
    Am Heart Hosp J; 2005; 3(2):105-10. PubMed ID: 15860997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dyslipidaemia, hypercoagulability and the metabolic syndrome.
    Kakafika AI; Liberopoulos EN; Karagiannis A; Athyros VG; Mikhailidis DP
    Curr Vasc Pharmacol; 2006 Jul; 4(3):175-83. PubMed ID: 16842135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The expanding scope of the metabolic syndrome and implications for the management of cardiovascular risk in type 2 diabetes with particular focus on the emerging role of the thiazolidinediones.
    Greenberg AS
    J Diabetes Complications; 2003; 17(4):218-28. PubMed ID: 12810246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic syndrome and progression of atherosclerosis among middle-aged US adults.
    Fan AZ
    J Atheroscler Thromb; 2006 Feb; 13(1):46-54. PubMed ID: 16505591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome.
    Devaraj S; Valleggi S; Siegel D; Jialal I
    Curr Atheroscler Rep; 2010 Mar; 12(2):110-8. PubMed ID: 20425246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The metabolic basis of atherogenic dyslipidemia.
    Vinik AI
    Clin Cornerstone; 2005; 7(2-3):27-35. PubMed ID: 16473258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of Dyslipidemia in Patients with Hypertension, Diabetes, and Metabolic Syndrome.
    Srikanth S; Deedwania P
    Curr Hypertens Rep; 2016 Oct; 18(10):76. PubMed ID: 27730495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.